Eleven private research-stage companies raised at least $60 million in one or more financing rounds between 2009-13. All 11 have a platform for generating multiple drug candidates. Notable platforms include cancer metabolism biology, antibodies/antibody-drug conjugates (ADCs) and RNA-based therapeutics. Four of the top six are explicitly developing treatments for rare diseases.

The companies were in discovery or preclinical development when they raised venture money over the 2009-13 period. Seven have since advanced lead programs into the clinic and three are now publicly traded. (A) Company declined to provide additional information on private financing rounds; Source: BCIQ: BioCentury Online Intelligence